New Research Findings
UCSD Patented Drug co-invented by Dr. Aceves on expedited pathway for FDA Approval
Children with genotype TT at the TGFb1 promoter have cells that are more pro-fibrotic and that do not localize adhesion molecules properly. Duong et al, Mucosal Immunology 2019
The long-term course of children with EoE reveals 3 distinct response patterns over time that can be distinguished by female sex and the first response to therapy. Collins, Palmquiest et al, Journal of Allergy and Clinical Immunology 2019
The Aceves and Kurten labs report a novel model functional ex vivo human mucosal platform to study EoE. Kurten et al. Scientific Reports 2019
New Grants
(NIH/NIAID) Probing the Mechanisms of Fibroblast-Extracellular Matrix Interactions to Asses Disease Severity in Allergic Eosinophilic Esophagitis
(NIH/NIAID/NIA) Study the potential relationship between EOE fibroblasts and pathogenic cells in Alzheimer's Disease
Active Grants
The Aceves lab is funded by the National Institutes of Health for research that unravels disease mechanisms and trains future researchers in Eosinophilic Gastrointestinal Disorders with an ultimate goal of improving patient lives.
NIH/NIAID. Contribution of Rigid Matrix to Allergic Eosinophilic Esophagitis Pathogenesis
NIH/NIAID. Pilot/Demonstration Cimical Research Projects Program
NIH/NIAID. Mentoring Patient Oriented Research in Allergic Eosinophilic Gastrointestinal Disorders
NIH/NIDDK. Light/TNFSF14 in Allergic Esophagitis Remodeling
NIH/NIAID/NIDDK/NCATS Consortium for Eosinophilic Gastrointestinal Researchers
UCSD Academic Senate Grant. Somatization, Anxiety, and Disordered Sleep in Children with Eosinophilic Esophagitis